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Which patients undergoing  
noncardiac surgery benefit from 
perioperative beta-blockers?
z Evidence summary
Studies without risk stratification 
find little benefit from beta-blockers
A systematic review including 25 ran-
domized controlled trials (RCTs) evalu-
ated perioperative beta-blocker therapy 
for noncardiac surgery in a total of 2722 
patients who were not stratified accord-
ing to cardiac risk status.1 
Perioperative beta-blockers produced 
no significant effect on:
•  all-cause mortality (odds ratio 
[OR]=0.78; 95% confidence inter-
val [CI], 0.33–1.87), 
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Patients	with	moderate	to	high	cardiac	risk	
(a	revised	Cardiac	risk	Index	[rCrI]	score	
of	2	or	higher	[TablE])	have	a	reduced	risk	
of	in-hospital	death	following	perioperative	
beta-blocker	therapy	(strength	of	
recommendation	[sor]:	B,	based	on	
a	large	retrospective	cohort	study).	
There	is,	however,	no	proven	benefit	to	
perioperative	beta-blocker	therapy	without	
prior	cardiac	risk	stratification	(sor:	A,	
based	on	systematic	reviews).
	 Perioperative	beta-blockers	reduce	
cardiovascular	risk	even	more	when	a	long-
acting	beta-blocker	(atenolol)	is	chosen	
over	a	shorter-acting	one	(metoprolol)		
(sor:	B,	based	on	a	retrospective	cohort	
study),	and	when	this	therapy	is	titrated	
to	a	target	heart	rate	of	<65	bpm	(sor:	B,	
based	on	cohort	studies).	
	 Perioperative	beta-blocker	therapy	
is	most	effective	when	initiated	at	least	
30	days	before	surgery	and	continued	
throughout	the	hospital	stay	(sor:	
C,	expert	opinion	extrapolated	from	
systematic	review).	Patients	already	on	
beta-blockers	before	surgery	should	
continue	at	least	through	the	perioperative	
period	(sor:	C,	expert	opinion).
Who better than you 
to reduce your patient’s risk?
Family	physicians	are	in	an	excellent	
position	to	assess	and	reduce	their	
patients’	risks	of	complications	from	
elective	surgery.	
	 While	perioperative	beta-blockers	
do	not	benefit	every	surgical	patient,	they	
do	benefit	certain	high-risk	patients.	In	
fact,	these	same	high-risk	patients	are	
often	candidates	for	chronic	beta-blocker	
therapy,	according	to	current	ACC/AHA	
guidelines.	Thus,	an	upcoming	surgery	
gives	us	another	opportunity	to	identify	
these	patients	and	get	them	treated.	
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Clinical commentary
Evidence-based answer
fast track
Perioperative  
beta-blockers  
did not reduce  
all-cause  
mortality or acute 
MI in studies  
without risk  
stratification
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C
l
in
iC
a
l
 I
n
q
u
Ir
Ie
s
122 vol	57,	no	2	/	FeBruArY	2008		ThE JournAl of fAmily PrACTiCE
•  acute myocardial infarction 
(OR=0.59; 95% CI, 0.25–1.39), 
•  atrial fibrillation/flutter and oth-
er supraventricular arrhythmias 
(OR=0.43; 95% CI, 0.14–1.37), or 
•  length of hospital stay (weighted 
mean difference, –5.6 days; 95% 
CI, –12.2, 1.04). 
However, in this review perioperative 
beta-blocker therapy reduced periopera-
tive myocardial ischemia (OR=0.38; 95% 
CI, 0.21–0.69), and increased 2 adverse 
outcomes: hemodynamically significant 
bradycardia (OR=1.98; 95% CI, 1.08–
3.66) and hypotension requiring treat-
ment (OR=2.52; 95% CI, 1.94–3.28).1 
This study was limited by the inconsistent 
definition and assessment of outcomes 
among the individual trials. 
no effect on total mortality, but a ben-
efit in a composite outcome.  An earlier 
systematic review with 22 RCTs and 2437 
total patients, that was also not stratified 
according to cardiac risk status, found no 
effect from perioperative beta-blockers on 
total mortality or cardiovascular mortality 
alone. However, it did demonstrate a com-
posite outcome of reduced cardiovascular 
mortality, reduced nonfatal myocardial 
infarction, and reduced nonfatal cardiac 
arrest (relative risk [RR]=0.44; 95% CI, 
0.20–0.97) 30 days after surgery.2 
beta-blockers benefit 
certain high-risk patients
A retrospective cohort study evaluated 
the effect of perioperative beta-blocker 
therapy on perioperative mortality, ac-
cording to preoperative RCRI assess-
ment.3 The study population included 
663,635 adults (mean age, 62 years) 
undergoing major noncardiac surgery at 
329 US hospitals. Researchers calculated 
individual RCRI scores (TablE).4 Half the 
patients had an RCRI of 0, 38% had an 
RCRI of 1, 10% had an RCRI of 2, and 
only 2% had an RCRI of 3 or greater. 
Be wary of beta-blockers in low-risk 
patients. In the 580,665 patients with low 
cardiac risk, perioperative beta-blocker 
therapy increased the risk of in-hospital 
death: for all patients with an RCRI of 0: 
OR=1.36 (95% CI, 1.27–1.45); number 
needed to harm (NNH)=208; for all pa-
tients with an RCRI of 1: OR=1.09 (95% 
CI, 1.01–1.19); NNH=504). 
A different story for high-risk cardiac 
patients. Perioperative beta-blocker ther-
apy reduced the risk of in-hospital death 
in patients with an RCRI of 2 (OR=0.88; 
95% CI, 0.80–0.98; number needed 
to treat [NNT]=227), an RCRI of 3 
(OR=0.71; 95% CI, 0.63–0.80; NNT=62), 
or an RCRI of 4 or more (OR=0.58; 95% 
CI, 0.50–0.67; NNT=33). 
long-acting beta-blockers =  
fewer MIs
A population-based, retrospective cohort 
analysis with 37,151 patients over 65 
years of age compared perioperative beta-
blocker therapy using atenolol (a long-
acting beta-blocker) with metoprolol (a 
shorter-acting beta-blocker) for elective 
surgery.5 Investigators excluded patients 
with symptomatic coronary disease. 
Perioperative 
beta-blockers 
reduced the risk of 
in-hospital death 
in patients with 
moderate to high 
cardiac risk—an 
RCRI of 2 or more
before surgery, calculate  
your patient’s cardiac risk
Assign 1 point for each of the following,  
and total:
•		High-risk	surgery	(intraperitoneal,	intrathoracic,		
or	suprainguinal	vascular	procedures)
•	History	of	ischemic	heart	disease
•	History	of	heart	failure
•	History	of	cerebrovascular	disease
•	Diabetes	mellitus	treated	with	insulin
•	serum	creatinine	>2.0	mg/dl
   risk of mAJor  
 PoinTs ClAss CArdiAC EvEnT*
	 0	 I	 0.4%	
	 1	 II	 0.9%	
	 2	 III		 6.6%	
	 3+	 Iv	 11%	
*Major	cardiac	event	includes	myocardial	infarction,	
pulmonary	edema,	ventricular	fibrillation,	primary	
cardiac	arrest,	and	complete	heart	block.
Source: lee	et	al,	1999.4
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Patients taking atenolol had fewer 
MIs (1.6% vs 2.0%, P=.004) and fewer 
deaths (1.2% vs 1.6%, P=.007) when 
compared with metoprolol. Atenolol pro-
duced a 13% relative risk reduction over 
metoprolol for MI or death after adjust-
ing for age, sex, type of surgery, and use 
of furosemide, calcium-channel blockers, 
angiotensin-converting enzyme inhibitors, 
and statins (comparative NNT=165).
Dose titration by heart rate
An observational cohort study with 272 
patients undergoing elective major vas-
cular surgery (mean age 67.4 years, 80% 
male) evaluated whether higher doses of 
beta-blockers and tight heart rate control 
reduced perioperative myocardial isch-
emia and troponin T release.6 Patients 
with higher beta-blocker doses, lower 
heart rates, and lower absolute change 
in heart rate during the perioperative 
period had significantly less periopera-
tive myocardial ischemia and troponin T 
release (P<.0001). 
The DECREASE-II trial, a prospec-
tive cohort study with 1476 patients un-
dergoing elective open abdominal aortic 
or infrainguinal arterial reconstruction 
also found that patients with heart rates 
<65 beats per minute had a significantly 
lower risk of cardiac death or MI at 30 
days postoperatively (1.3% vs 5.2%, 
OR=0.24; 95% CI, 0.09–0.66).7 
begin therapy  
30 days before surgery
Authors of a systematic review includ-
ing 5 RCTs (586 total patients) evaluat-
ing perioperative beta-blocker therapy in 
noncardiac surgery concluded that beta-
blocker therapy should begin as long as 
30 days prior to surgery to allow for ti-
tration of dose to the target heart rate and 
continue at least throughout hospitaliza-
tion (longer if adequate medical follow-
up can be arranged postoperatively).8 
Recommendations from others
The American College of Cardiology/
American Heart Association Task Force 
on Practice Guidelines9 recommends:
• continuing beta-blockers for pa-
tients already receiving them to treat 
angina, symptomatic arrhythmias, and 
hypertension before their surgical risk 
evaluation. 
• initiating perioperative beta-
blocker therapy for patients undergo-
ing vascular surgery if they are at high 
cardiac risk, as evidenced by ischemia on 
preoperative testing.
• considering perioperative beta-
blocker therapy for patients undergoing 
intermediate- to high-risk procedures if 
preoperative risk assessment identifies 
them as having intermediate or higher 
cardiac risk, and for patients undergoing 
vascular surgery who are at low cardiac 
risk. n 
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